Payment overview · 2025
General Payments
$2,256.51
108 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher A Haddad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SAN ANGELO, TX · NPI 1912987264
Verified facts
What the public records show
CMS Open Payments records show Christopher A Haddad, M.D. received $2,256.51 in general payments during 2025 across 108 reported records.
ABIOMED accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 515 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 515 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $783.76 | 34.7% | 48 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $538.70 | 23.9% | 23 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$210.43 | 9.3% | 12 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $178.60 | 7.9% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $123.33 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $107.02 | 4.7% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.24 | 3.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $61.74 | 2.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.71 | 2.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.56 | 2.1% | 3 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $44.54 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.99 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.89 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,256.51 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $178.60 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $172.59 | 10 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $151.11 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $123.33 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $113.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $107.02 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.24 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $75.51 | 4 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $67.13 | 5 | 2025 |
Source payment records
|
|||||
| VIEWMATE Normalized: viewmate |
Device | Abbott Laboratories | $53.00 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $37.79 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $34.79 | 2 | 2025 |
Source payment records
|
|||||
| PRECISE PRO RX Normalized: precise pro rx |
Device | CORDIS US CORP. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $27.76 | 2 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $16.00 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| ABSOLUTE PRO Normalized: absolute pro |
Device | Abbott Laboratories | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ARMADA Normalized: armada |
Device | Abbott Laboratories | $11.08 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $5.51 | 1 | 2025 |
Source payment records
|
|||||
| OMNILINK ELITE Normalized: omnilink elite |
Device | Abbott Laboratories | $3.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 515 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
216 | 66 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
515 | 131 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
220 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
515 | 131 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1198 | 369 |
| Lisinopril | Lisinopril | 926 | 280 |
| Furosemide | Furosemide | 907 | 300 |
| Clopidogrel | Clopidogrel Bisulfate | 812 | 247 |
| Carvedilol | Carvedilol | 695 | 231 |
| Metoprolol Succinate | Metoprolol Succinate | 645 | 207 |
| Eliquis | Apixaban | 515 | 131 |
| Potassium Chloride | Potassium Chloride | 485 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 468 | 145 |
| Losartan Potassium | Losartan Potassium | 457 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 145 |
| Metoprolol Tartrate | Metoprolol Tartrate | 379 | 141 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 356 | 104 |
| Ezetimibe | Ezetimibe | 349 | 98 |
| Ranolazine Er | Ranolazine | 307 | 74 |
| Nifedipine Er | Nifedipine | 298 | 101 |
| Warfarin Sodium | Warfarin Sodium | 242 | 57 |
| Spironolactone | Spironolactone | 230 | 72 |
| Repatha Sureclick | Evolocumab | 228 | 51 |
| Nitroglycerin | Nitroglycerin | 223 | 158 |
| Entresto | Sacubitril/Valsartan | 220 | 52 |
| Brilinta | Ticagrelor | 216 | 66 |
| Simvastatin | Simvastatin | 199 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 65 |
| Xarelto | Rivaroxaban | 171 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 143 | 49 |
| Atenolol | Atenolol | 122 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Farxiga | Dapagliflozin Propanediol | 96 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | 21 |
| Vascepa | Icosapent Ethyl | 66 | 21 |
| Gemfibrozil | Gemfibrozil | 60 | 14 |
| Torsemide | Torsemide | 49 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 41 | 11 |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Praluent Pen | Alirocumab | 36 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Sotalol | Sotalol Hcl | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | suppressed |
| Repatha Syringe | Evolocumab | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,256.51 · 108 records | ABIOMED | ABSOLUTE PRO, ARMADA, CAMZYOS, CARDIOMEMS, COREVALVE EVOLUT R, COROFLOW, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ELIQUIS, ESPRIT, Indigo System, JARDIANCE, LEQVIO, LOKELMA, MYNX CONTROL VENOUS, OMNILINK ELITE, PERCLOSE PROSTYLE, PRECISE PRO RX, PRESSUREWIRE, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, ULTREON, VERQUVO, VIEWMATE, Wegovy, XIENCE SKYPOINT | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error